Mostrar el registro sencillo del ítem

dc.contributor.authorHervás-Corpión, Irati
dc.contributor.authorGallardo-orihuela, Andrea
dc.contributor.authorCatalina-Fernández, Inmaculada
dc.contributor.authorIglesias-Lozano, Irene
dc.contributor.authorSoto-Torres, Olga
dc.contributor.authorGeribaldi Doldán, Noelia 
dc.contributor.authorDomínguez García, Samuel 
dc.contributor.authorLuna-García, Nuria
dc.contributor.authorRomero‑García, Raquel
dc.contributor.authorMora‑López, Francisco
dc.contributor.authorIriarte-Gahete, Marianela
dc.contributor.authorMorales, Jorge C.
dc.contributor.authorCampos Caro, Antonio 
dc.contributor.authorCastro González, Carmen 
dc.contributor.authorGil-Salú, José L.
dc.contributor.authorValor, Luis M.
dc.contributor.otherAnatomía y Embriología Humanaes_ES
dc.contributor.otherBiomedicina, Biotecnología y Salud Públicaes_ES
dc.date.accessioned2022-01-21T10:34:49Z
dc.date.available2022-01-21T10:34:49Z
dc.date.issued2021-11
dc.identifier.issn2072-6694
dc.identifier.urihttp://hdl.handle.net/10498/26055
dc.description.abstractSimple Summary:& nbsp;In the search of the key factors that differentiate the aggressive glioblastomas from lower-grade gliomas, we determined that the variants of the structural protein of the nucleosome histone H3 show different degrees of expression. In general, high expression of H3.1/H3.2 was associated with clinical features of glioblastomas whereas high expression of H3.3 was linked to molecular alterations found in low-grade gliomas. In fact, those glioblastomas showing low expression levels of H3.1/H3.2 are highly similar to low-grade gliomas, suggesting an association with glioma aggressiveness that deserves further investigation in large cohorts. Glioblastoma (GB) is the most aggressive form of glioma and is characterized by poor prognosis and high recurrence despite intensive clinical interventions. To retrieve the key factors underlying the high malignancy of GB with potential diagnosis utility, we combined the analysis of The Cancer Gene Atlas and the REMBRANDT datasets plus a molecular examination of our own collection of surgical tumor resections. We determined a net reduction in the levels of the non-canonical histone H3 variant H3.3 in GB compared to lower-grade astrocytomas and oligodendrogliomas with a concomitant increase in the levels of the canonical histone H3 variants H3.1/H3.2. This increase can be potentially useful in the clinical diagnosis of high-grade gliomas, as evidenced by an immunohistochemistry screening of our cohort and can be at least partially explained by the induction of multiple histone genes encoding these canonical forms. Moreover, GBs showing low bulk levels of the H3.1/H3.2 proteins were more transcriptionally similar to low-grade gliomas than GBs showing high levels of H3.1/H3.2. In conclusion, this study identifies an imbalanced ratio between the H3 variants associated with glioma malignancy and molecular patterns relevant to the biology of gliomas, and proposes the examination of the H3.3 and H3.1/H3.2 levels to further refine diagnosis of low- and high-grade gliomas in future studies.es_ES
dc.description.sponsorshipL.M.V. is supported by Programa Estatal de Generacion de Conocimiento y Fortalecimiento del Sistema Espanol de I+D+i and financed by Instituto de Salud Carlos III and Fondo Europeo de Desarrollo Regional 2014-2020 (grants CP15/00180, PI16/00722, PI19/00125) and by Plan Propio INiBICA (grant L19-07IN-CO07). A.C.-C. is supported by Programa Estatal de Generacion de Conocimiento y Fortalecimiento del Sistema Espanol de I+D+i and financed by Instituto de Salud Carlos III and Fondo Europeo de Desarrollo Regional 2014-2020 (grant PI15/01147). C.C. is supported by Ministerio de Ciencia e Innovacion (grant RTI2018-099908-B-C21) and Consejeria de Economia, Conocimiento, Empresas y Universidades convocatoria de proyectos I+D+i en el marco operativo FEDER-Andalucia (grant sol-2018-00106647-tra). L.M.V. is the recipient of a Miguel Servet I contract (CP15/00180) followed by a Miguel Servet II contract (CPII20/00025), and J.C.M is the recipient of a Rio Hortega contract (CM18/00043), financed by Instituto de Salud Carlos III and Fondo Social Europeo 2014-2020, Programa Estatal de Promocion del Talento y su empleabilidad en I+D+i.es_ES
dc.formatapplication/pdfes_ES
dc.language.isoenges_ES
dc.publisherMDPIes_ES
dc.rightsAtribución 4.0 Internacional*
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/*
dc.sourceCancers 2021, 13(21), 5261es_ES
dc.subjectglioblastomaes_ES
dc.subjectastrocytomaes_ES
dc.subjectoligodendrogliomaes_ES
dc.subjectH3.1/H3.2es_ES
dc.subjectH3.3es_ES
dc.subjectH3F3Bes_ES
dc.subjectHIST1H3Fes_ES
dc.subjectHIST1H3Ges_ES
dc.subjectHIST1H3Jes_ES
dc.subjectdiagnosises_ES
dc.subjectRNA-seqes_ES
dc.titlePotential Diagnostic Value of the Differential Expression of Histone H3 Variants between Low- and High-Grade Gliomases_ES
dc.typejournal articlees_ES
dc.rights.accessRightsopen accesses_ES
dc.identifier.doi10.3390/cancers13215261
dc.relation.projectIDinfo:eu-repo/grantAgreement/AEI/Plan Estatal de Investigación Científica y Técnica y de Innovación 2017-2020/RTI2018-099908-B-C21/ES/TERAPIAS DE REEMPLAZO NEURONAL EN DOS MODELOS ANIMALES DE DAÑO CEREBRAL: HACIA LA BUSQUEDA DE NUEVO FARMACOS/es_ES
dc.relation.projectIDinfo:eu-repo/grantAgreement/MINECO//CP15%2F00180/ES/CP15%2F00180/es_ES
dc.relation.projectIDinfo:eu-repo/grantAgreement/MINECO//PI16%2F00722/ES/Biomarcadores y dianas del núcleo celular en enfermedades neurodegenerativas de trinucleótidos/es_ES
dc.relation.projectIDinfo:eu-repo/grantAgreement/MINECO//PI19%2F00125/es_ES
dc.relation.projectIDinfo:eu-repo/grantAgreement/MINECO//PI15%2F01147/ES/Diferenciación de las células plasmáticas humanas en la salud y en la enfermedad: análisis de la expresión génica de célula única en Lupus Eritrematoso Sistémico y en Artritis Reumatoide/es_ES
dc.relation.projectIDinfo:eu-repo/grantAgreement/MINECO//CP15%2F00180/ES/CP15%2F00180/es_ES


Ficheros en el ítem

Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo del ítem

Atribución 4.0 Internacional
Esta obra está bajo una Licencia Creative Commons Atribución 4.0 Internacional